



Julia Scherrer

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Julia Scherrer
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 1179
Julia.Scherrer@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

study nurse

Publications (0)

No results found.

Projects (8)

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Clinical Studies - Jan 26, 2024 - Dec 31, 2027

Ongoing

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Clinical Studies - Nov 28, 2022 - Dec 31, 2026

Completed

Studie zu NIS793 oder Placebo zusammen mit Gemcitabin und nab-Paclitaxel bei Teilnehmern mit metastasiertem duktalem Adenokarzinom der Bauchspeicheldrüse (mPDAC)

Clinical Studies - Nov 14, 2022 - Jan 31, 2026

Completed

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1

Clinical Studies - Sep 9, 2022 - Dec 31, 2026

Completed

Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Clinical Studies - Aug 23, 2022 - Aug 24, 2030

Ongoing

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Clinical Studies - Aug 9, 2022 - Dec 31, 2027

Ongoing

Muscle-invasive bladder cancer (MIBC) and perioperative treatment

Clinical Studies - May 13, 2022 - May 13, 2032

Ongoing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Studies - Apr 22, 2021 - May 20, 2030

Completed

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch